Second consensus on medical treatment of metastatic breast cancer

被引：80

作者：

Beslija, S. ^{[1
]}

Bonneterre, J. ^{[1
]}

Burstein, H. ^{[1
]}

Cocquyt, V. ^{[1
]}

Gnant, M. ^{[1
]}

Goodwin, P. ^{[1
]}

Heinemann, V. ^{[1
]}

Jassem, J. ^{[1
]}

Koestler, W. J. ^{[1
]}

Krainer, M. ^{[1
]}

Menard, S. ^{[1
]}

Petit, T. ^{[1
]}

Petruzelka, L. ^{[1
]}

Possinger, K. ^{[1
]}

Schmid, P. ^{[1
]}

Stadtmauer, E. ^{[1
]}

Stockler, M. ^{[1
]}

Van Belle, S. ^{[1
]}

Vogel, C. ^{[1
]}

Wilcken, N. ^{[1
]}

Wiltschke, C. ^{[1
]}

Zielinski, C. C. ^{[1
]}

Zwierzina, H. ^{[1
]}

机构：

[1] CECOG, A-1090 Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷 / 02期

关键词：

chemotherapy; endocrine therapy; medical treatment; metastatic breast cancer; targeted therapy;

D O I：

10.1093/annonc/mdl155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

引用

页码：215 / 225

页数：11

共 101 条

[61] Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J].

Miller, KD ;

Chap, LI ;

Holmes, FA ;

Cobleigh, MA ;

Marcom, PK ;

Fehrenbacher, L ;

Dickler, M ;

Overmoyer, BA ;

Reimann, JD ;

Sing, AP ;

Langmuir, V ;

Rugo, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :792-799

[62] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group [J].

Mouridsen, H ;

Gershanovich, M ;

Sun, Y ;

Pérez-Carrión, R ;

Boni, C ;

Monnier, A ;

Apffelstaedt, J ;

Smith, R ;

Sleeboom, HP ;

Jänicke, F ;

Pluzanska, A ;

Dank, M ;

Becquart, D ;

Bapsy, PP ;

Salminen, E ;

Snyder, R ;

Lassus, M ;

Verbeek, JA ;

Staffler, B ;

Chaudri-Ross, HA ;

Dugan, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2596-2606

[63] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group [J].

Mouridsen, H ;

Gershanovick, M ;

Sun, Y ;

Pérez-Carrión, R ;

Boni, C ;

Monnier, A ;

Apffelstaedt, J ;

Smith, R ;

Sleeboom, HP ;

Jaenicke, F ;

Pluzanska, A ;

Dank, M ;

Becquart, D ;

Bapsy, PP ;

Salminen, E ;

Snyder, R ;

Chaudri-Ross, H ;

Lang, R ;

Wyld, P ;

Bhatnagar, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2101-2109

[64]

Mouridsen H, 2002, BREAST CANCER RES TR, V76, pS88

[65] Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial [J].

Nabholtz, JM ;

Buzdar, A ;

Pollak, M ;

Harwin, W ;

Burton, G ;

Mangalik, A ;

Steinberg, M ;

Webster, A ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3758-3767

[66] Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results [J].

Nabholtz, JM ;

Bonneterre, J ;

Buzdar, A ;

Robertson, JFR ;

Thürlimann, B .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) :1684-1689

[67] Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer [J].

Nabholtz, JM ;

Gelmon, K ;

Bontenbal, M ;

Spielmann, M ;

Catimel, G ;

Conte, P ;

Klaassen, U ;

Namer, M ;

Bonneterre, J ;

Fumoleau, B ;

Winograd, B .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1858-1867

[68] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial [J].

Nabholtz, JM ;

Falkson, C ;

Campos, D ;

Szanto, J ;

Martin, M ;

Chan, S ;

Pienkowski, T ;

Zaluski, J ;

Pinter, T ;

Krzakowski, M ;

Vorobiof, D ;

Leonard, R ;

Kennedy, I ;

Azli, N ;

Murawsky, M ;

Riva, A ;

Pouillart, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :968-975

[69] Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists' preferences [J].

Nooij, MA ;

de Haes, JCJM ;

Beex, LVAM ;

Wildiers, J ;

Klijn, J ;

Becquart, D ;

Jassem, J ;

Engelsman, E ;

Duchateau, L .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (05) :614-621

[70] Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer [J].

O'Brien, MER ;

Wigler, N ;

Inbar, M ;

Rosso, R ;

Grischke, E ;

Santoro, A ;

Catane, R ;

Kieback, DG ;

Tomczak, P ;

Ackland, SP ;

Orlandi, F ;

Mellars, L ;

Alland, L ;

Tendler, C .

ANNALS OF ONCOLOGY, 2004, 15 (03) :440-449

← 2 3 4 5 6 7 8 9 10 11 →